Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer

The Oncologist, 04/26/2012

First–line capecitabine monotherapy has a favorable safety profile, lacking myelosuppression and alopecia, and does not compromise the administration of further lines of chemotherapy. Capecitabine is suitable for long–term administration without the cumulative toxicity that can limit the prolonged use of other chemotherapy agents.

Print Article Summary Cat 2 CME Report